Stockscreener 앱 받기
15.78
3.90%
-0.64
시간 외 거래:
16.78
1.00
+6.34%
전일 마감가:
$16.42
열려 있는:
$15.85
하루 거래량:
1.76M
Relative Volume:
1.18
시가총액:
$2.68B
수익:
-
순이익/손실:
$-323.01M
주가수익비율:
-7.1081
EPS:
-2.22
순현금흐름:
$-272.30M
1주 성능:
-16.02%
1개월 성능:
-14.43%
6개월 성능:
-46.11%
1년 성능:
-49.39%
1일 변동 폭
$15.44
$16.19
1주일 범위
$14.90
$18.82
52주 변동 폭
$14.90
$34.47
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-580-3099
주소
320 WEST 37TH STREET, NEW YORK, NY
IMVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
15.78 | 2.68B | 0 | -323.01M | -272.30M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Teacher Retirement System of Texas Has $377,000 Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) PT at $41.00 - Defense World
How the (IMVT) price action is used to our Advantage - news.stocktradersdaily.com
Immunovant stock hits 52-week low at $17.01 amid market challenges - Investing.com
Swiss National Bank Grows Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Batoclimab eases disease severity; Immunovant backs IMVT-1402 - Myasthenia Gravis News
Guggenheim Reiterates Buy Rating for Immunovant (NASDAQ:IMVT) - MarketBeat
Teenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win, but shifts focus; Alnylam’s big moment; and more - Endpoints News
Charles Schwab Investment Management Inc. Increases Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Bank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock Price - Defense World
Immunovant price target raised to $61 from $58 at Stifel - Yahoo Finance
Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com
HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT) - Defense World
Immunovant stock hits 52-week low at $17.15 amid market challenges - Investing.com Australia
Stifel raises Immunovant stock price target to $61 from $58 By Investing.com - Investing.com Canada
Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate - TradingView
Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright - Yahoo Finance
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success - TradingView
Immunovant stock holds $51 target on positive trial data By Investing.com - Investing.com Canada
Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Victory Capital Management Inc. - Defense World
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) - Seeking Alpha
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data - AOL
Immunovant’s Batoclimab Shows Promising Efficacy in MG and CIDP, Justifying Buy Rating - TipRanks
Immunovant will not seek approval for MG therapy, despite hitting endpoints - Yahoo Finance
Immunovant's muscle drug meets main goal, shares gain on new drug promise - Reuters.com
Immunovant claims study success for immune disease drug but holds off on submission - BioPharma Dive
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another - BioSpace
Immunovant stock hits 52-week low at $17.15 amid market challenges By Investing.com - Investing.com South Africa
Positive batoclimab data from Immunovant, but doubts raised on further development - The Pharma Letter
En garde, Vyvgart: Immunovant rolls out MG data - BioWorld MedTech
Immunovant's muscle drug data underwhelms, shares gain on new drug promise -March 19, 2025 at 08:12 am EDT - Marketscreener.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Immunovant stock Roivant stock slip on trial data (IMVT) - Seeking Alpha
Immunovant Says Currently Not Planning to Seek Approval of Batoclimab for Myasthenia Gravis; Shares Drop Pre-Bell - Marketscreener.com
Immunovant reports promising Phase 3 MG study results - Investing.com India
Roivant Sciences Announces Positive Results for Batoclimab Studies - TipRanks
Immunovant's muscle disorder treatment meets main goal in late-stage trial -March 19, 2025 at 08:12 am EDT - Marketscreener.com
Immunovant stock falls despite study success By Investing.com - Investing.com South Africa
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies - The Manila Times
Immunovant stock falls despite study success - Investing.com
Immunovant's muscle disorder treatment meets main goal in late-stage trial -March 19, 2025 at 07:52 am EDT - MarketScreener
Immunovant reports promising Phase 3 MG study results By Investing.com - Investing.com UK
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - The Manila Times
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - The Manila Times
Immunovant, Inc. to Host Investor Webcast on Phase 3 Study Results of Batoclimab in MG and Phase 2b Study in CIDP - Nasdaq
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from - Bakersfield.com
Critical Phase 3 Results: Immunovant's Breakthrough MG and CIDP Treatment Data Reveal Coming Next Week - StockTitan
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? - AOL
Immunovant director Andrew Fromkin sells $156,768 in stock By Investing.com - Investing.com Australia
Immunovant director Andrew Fromkin sells $156,768 in stock - Investing.com India
Immunovant’s (IMVT) Buy Rating Reaffirmed at Guggenheim - Defense World
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):